Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Date:12/8/2008

cal and related costs of obesity are $123 billion per year according to a 2005 report by the International Diabetes Federation. Being obese or overweight is associated with increased risk of a number of conditions, including heart disease, stroke, diabetes, cancer and osteoarthritis. Medical treatment options for obese and overweight people currently are limited.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication, tolerability, side effects, efficacy and potential of lorcaserin; future results of clinical trials; future activities and announcements relating to lorcaserin, including the BLOOM results and the submission of an NDA for lorcaserin; and about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ mater
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
3. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
4. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
5. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
6. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
8. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Follow us on LinkedIn – Breast ... from the breast of a lactating mother through the suction ... feeding the baby. Breast pumps are used when direct feeding ... the mother being away from a child for a longer ... pumps are also used to stimulate lactation and relieve engorgement ...
(Date:3/4/2015)... 2015 Brassica Protection Products LLC, an ... rebrand of its SGS™ brand of glucoraphanin to truebroc™. ... glucoraphanin, which is the most concentrated source of glucoraphanin ... includes a new truebroc logo and refreshed website and ... brand name. , “We are thrilled to unveil ...
(Date:3/4/2015)... Whatever one's feelings about the Fifty Shades of Grey™ phenomenon, ... hard-core fans of the trilogy, to people in the BDSM ... even one of the books, is putting their two cents ... manager of HUSH, a leading retailer of adult sexual health ... thing. , "When the books came out in 2011 we ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The defibrillators ... defibrillators market. According to the report the global market ... from 2014 to reach $12.9 billion by 2019. It ... for the potential as well as established players in ... Asia-Pacific are positioned to witness growth at the highest ...
(Date:3/4/2015)... 2015 TheraBreath is proud to announce a ... could also help with overall health. , Many health ... help ward off bad bacteria that can cause unwanted infections. ... their own, most will need the help of a probiotic ... fighting levels. , Packed with the S. salivarius M18 & ...
Breaking Medicine News(10 mins):Health News:Increase in the Number of Nursing Mothers in the Workplace Spurs the Breast Pumps Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Increase in the Number of Nursing Mothers in the Workplace Spurs the Breast Pumps Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Brassica Protection Products Rebrands its SGS™ Brand of Glucoraphanin to truebroc™ 2Health News:Fifty Shades of Grey™ Has Canadians Talking About Sex. 2Health News:Defibrillators Market worth $12.9 Billion by 2019 with Rise in Aging Population - New Research Report by MarketsandMarkets 2Health News:Defibrillators Market worth $12.9 Billion by 2019 with Rise in Aging Population - New Research Report by MarketsandMarkets 3Health News:TheraBreath introduces a new line of probiotic lozenges that strengthen the body’s ability to fight germs 2
... , SAN FRANCISCO, July 23 The ... and transgender civil rights organization, today announced its speakers for ... 25, 2009, at the Westin St. Francis Hotel in San ... discuss issues impacting the LGBT community,s strive for human rights ...
... , , , ... announced that after laboratory analysis of electronic cigarette samples they have ... this does not ring true for U.S. based manufacturer, SmokeStik ... cartridges and listed several compounds of concern, such as, Diethylene Glycol, ...
... , WASHINGTON, July 23 The Community Oncology Alliance ... patients and community providers of cancer care, has responded in a ... , "We strongly support President Obama,s guiding ... fix what is broken., Unfortunately, that is the exact opposite of ...
... , WASHINGTON, July 23 The American ... president and CEO of Truman Medical Centers in Kansas City, Mo. ... 2011, becoming the top elected official of the national organization that ... , Bluford has been chief executive officer and ...
... , , , ... ALGN ) today reported financial results for the second quarter, ended June ... the second quarter of fiscal 2009 (Q2 09) were $76.3 million compared to $70.1 ... million reported in the second quarter of 2008 (Q2 08). Invisalign case shipments ...
... , SACRAMENTO, Calif., July 23 Oscar ... and Kipp Berdiansky, co-owner of the Psycho Donuts shop, participated in an ... host Rosy Chu. , , Oscar ... "As the former regional administrator of the U.S. Small Business Administration, ...
Cached Medicine News:Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 2Health News:Human Rights Campaign Announces Speakers at 25th Annual Bay Area Gala 3Health News:RESPONSE to the FDA and Public Health Experts Findings on Electronic Cigarettes 2Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 2Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 3Health News:The Community Oncology Alliance Responds to President Obama's Press Conference Comments Regarding Cancer Patients 4Health News:AHA Board Elects John Bluford Chair-Elect Designate 2Health News:AHA Board Elects John Bluford Chair-Elect Designate 3Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 2Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 3Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 4Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 5Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 6Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 7Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 8Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 9Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 10Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 11Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 12Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 13Health News:Align Technology Announces Second Quarter Fiscal 2009 Results 14Health News:Mental Health Advocates Call for Psycho Donuts to Do the Right Thing 2
(Date:3/4/2015)... Mass. , March 4, 2015   HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is ... Conference at 8:00 a.m. Eastern Time on Tuesday, March ... at the Loews Miami Beach Hotel in ...
(Date:3/4/2015)... Ga., March 4, 2015  Halyard Health, Inc. (NYSE: ... and provided its 2015 outlook and related key planning ... Halyard Health as we report our fourth quarter results, ... Chairman and CEO. "We executed a smooth separation from ... the spin-off. We delivered sales growth and margin improvement ...
(Date:3/4/2015)... March 4, 2015   InspireMD, Inc.  ("InspireMD" or ... protection systems ("EPS"), today announced that it has entered ... 34 million shares of common stock and warrants to ... stock in a public offering.  The common stock will ... per share, and each purchaser will receive a warrant ...
Breaking Medicine Technology:HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 2Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 3Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 4Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 5Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 6Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 7Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 8Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 9Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 10Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 11Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 12Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 13Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 14Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 15Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 16Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 17Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 18Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 19Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 20Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 21Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 22Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 23Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 24Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 25Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 26Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 27Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 28Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 29Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 30Halyard Health, Inc. Announces Year-End 2014 Results and 2015 Outlook 31InspireMD Announces Public Offering for Approximately $13.5 Million 2InspireMD Announces Public Offering for Approximately $13.5 Million 3InspireMD Announces Public Offering for Approximately $13.5 Million 4
... April 7, 2008 Genta,Incorporated (Nasdaq: GNTA ... Injection, the Company,s lead anticancer,compound will be featured ... Cancer Research (AACR). The meeting will be held ... subject matter of several abstracts, which are,relevant to ...
... SAN FRANCISCO, April 4, 2008 VIA,Pharmaceuticals (Nasdaq: ... the,development of compounds for the treatment of cardiovascular ... Board (DSMB),for its VIA-2291 Phase 2 clinical trial ... current Phase 2 studies. The DSMB observed a,continued ...
Cached Medicine Technology:Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 2Specialized Genasense(R) Clinical Trials Featured at AACR Meeting 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 2VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 3VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program 4
This 1000 L tip is the equivalent to the "Blue" tips and fits nearly every manufacturer's 1000 L pipettor....
Conducting disposable filter-tips....
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting....
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
Medicine Products: